Fallopian Tube Undifferentiated Carcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive carcinoma arising from the fallopian tube. It is characterized by the presence of a diffuse malignant infiltrate that is composed of epithelial cells without evidence of glandular or squamous differentiation. 
There are 9 clinical trials for fallopian tube undifferentiated carcinoma, of which 8 are open and 1 is completed or closed. Of the trials that contain fallopian tube undifferentiated carcinoma as an inclusion criterion, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).
BRCA1, BRCA2, and NT5E are the most frequent gene inclusion criteria for fallopian tube undifferentiated carcinoma clinical trials .
Carboplatin, paclitaxel, and anlotinib are the most common interventions in fallopian tube undifferentiated carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.